© EQS Newswire
19.11.2024
SOON
LISTED
SIX
Solid sales growth in the first half, acceleration through successful platform launches expected
News Preview
Group Media & Investor ReleaseAd hoc announcement pursuant to Art. 53 LR
Staefa (Switzerland), November 19, 2024 – Sonova Holding AG, a leading provider of hearing solutions, today announces results for the first half of its 2024/25 financial year. Group sales reached CHF 1,833.2 million, an increase of 5.9% in local currencies, driven by a str......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.11.2024
SOON
LISTED
SIX
Solides Umsatzwachstum im ersten Halbjahr, Beschleunigung durch erfolgreiche Plattformeinführungen erwartet
News Preview
Group Media & Investor ReleaseAd hoc-Mitteilung gemäss Art. 53 KR
Stäfa (Schweiz), 19. November 2024 – Sonova Holding AG, ein führender Anbieter von Hörlösungen, gibt heute das Ergebnis für das erste Geschäftshalbjahr 2024/25 bekannt. Der Gruppenumsatz erreichte CHF 1’833,2 Mio., was einem Anstieg von 5,9 % in Lokalwährungen entspricht, bedingt......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.11.2024
FYB
LISTED
XETR
Formycon lädt zum Earnings-Call für das Neunmonatsergebnis 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
News Preview
Pressemitteilung // 19. November 2024
Formycon lädt zum Earnings-Call für das Neunmonatsergebnis 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Planegg-Martinsried - Die Formycon AG (FWB: FYB, „Formycon“) lädt zur Telefonkonferenz und zum Webcast zur Veröffentlichung des Neunmonatsergebnisses 2024 am 28. November 20......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
19.11.2024
FYB
LISTED
XETR
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
News Preview
Press Release // November 19, 2024
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, „Formycon“) invites to the conference call and webcast for the publication of the nine-month results 2024 on November 28, 2024.......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
18.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
News Preview
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
News Preview
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia
- Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes
- Two Iomab-ACT INDs cleared by FDA:...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
HELP
LISTED
NASDAQ
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deut...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
DFTX
LISTED
NASDAQ
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Com...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study
News Preview
STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary Biliary Cholangitis. The preliminary results show that golexanolo...
Themefolio
Profiler
Peergroup
© EQS Newswire
18.11.2024
FYB
LISTED
XETR
Formycon erhält positive CHMP-Empfehlung für FYB203 (Aflibercept), einen Biosimilar-Kandidaten für Eylea®, unter den Markennamen AHZANTIVE® und Baiama®
News Preview
Pressemitteilung // 18. November 2024
Formycon erhält positive CHMP-Empfehlung für FYB203 (Aflibercept), einen Biosimilar-Kandidaten für Eylea®, unter den Markennamen AHZANTIVE® und Baiama®
Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) empfiehlt die Zulassung von FYB203 zur Behandlung der neovaskulären alter......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.11.2024
FYB
LISTED
XETR
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
News Preview
Press Release // November 18, 2024
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of FYB203 for the treatment of Neovascular Age-Related ......
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
ICLR
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Ico...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
15.11.2024
ICLR
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company’s possible violations of federal securities laws.
On October 23, 2024, Icon released its third quarter 2024 financial results, missing consensus estimates “due to specific cu...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.11.2024
FYB
LISTED
XETR
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Planegg-Martinsried, Germany, November 15, 2024 – Formycon (FSE: FYB, "Formycon“) announces that the European Medicines Agency (EMA) published today that the Co......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.11.2024
FYB
LISTED
XETR
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® erhält CHMP-Empfehlung der EMA
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama®erhält CHMP-Empfehlung der EMA
Planegg-Martinsried, Deutschland, 15. November 2024 – Die Formycon AG (FWB: FYB, "Formycon“) gibt bekannt, dass die Europäischen Arzneimittel-Agentur (EMA) am heutigen Tag......
Themefolio
Profiler
Peergroup
© PR Newswire
15.11.2024
IMMNOV
LISTED
STO
Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas--Inherited Gastrointestinal Cancers
News Preview
PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company's next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC)....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
KDEV
LISTED
STO
Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO
News Preview
STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from today, Friday November 15th, as Dr Richard Bethell has decided to step down as CEO to pursue other professional in...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
KDEV
LISTED
STO
Interim Report - January-September 2024
News Preview
STOCKHOLM – 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-September 2024. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
BAVA
LISTED
CPH
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
News Preview
COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.11.2024
CLBX
LISTED
AIMX
Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR
News Preview
RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancerGUILDFORD, SURREY / ACCESSWIRE / Novem...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.11.2024
CLBX
LISTED
AIMX
Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR
News Preview
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug d...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
News Preview
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS.
The gross proce...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
ICLR
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz announces an investigation of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On October 23, 2024, Icon released its third...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.11.2024
EVT
LISTED
XETR
Kommentar zu Medienbericht
News Preview
Ad hoc: Kommentar zu Medienbericht
Hamburg – Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)
Die Evotec SE ("Gesellschaft") stellt mit Blick auf einen Medienbericht fest, dass sie ohne vorherige Kontaktaufnahme vom börsennotierten US-Biotechnologieunternehmen Halozyme Thera......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.11.2024
EVT
LISTED
XETR
Comment on media report
News Preview
Ad hoc: Comment on media report
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)
With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology ......
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
TRAW
LISTED
NASDAQ
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
News Preview
NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases, today outlined recent business updates and reported unaudited financial results for the third quarter ended September 30, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
BIOA B
LISTED
STO
CHMP issues positive recommendation for approval of lecanemab in the EU
News Preview
STOCKHOLM, Nov. 14, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recomme...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
BIOA B
LISTED
STO
CHMP issues positive recommendation for approval of lecanemab in the EU
News Preview
STOCKHOLM, Nov. 14, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recomme...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.11.2024
EVT
LISTED
XETR
Comment on Media Report
News Preview
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotec...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
LIVN
LISTED
NASDAQ
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December:
Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
HELP
LISTED
NASDAQ
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
COLO B
LISTED
CPH
Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy
News Preview
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.11.2024
AGFB
LISTED
EURONEXT
AGFA HealthCare Expands the Enterprise Imaging Platform to Cardiology at Zuckerberg San Francisco General Hospital
News Preview
Breaking down the silos between departments opens up an exciting new level of efficiency, cost savings, communication, and faster, more informed decision-making.SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2024 / AGFA HealthCare, a global leader and pioneer in care delivery and Enterprise Imaging (EI) technology, is thrilled to announce the expans...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
BLUE
LISTED
NASDAQ
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress.
“Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial la...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
News Preview
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond™ Phase 2 clinical trial assessing nimacimab, a...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
SECT_B
LISTED
STO
Sectra receives CSA STAR Level 2 security certificate--facilitating cloud adoption in healthcare
News Preview
LINKÖPING, Sweden, Nov. 14, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received CSA STAR Level 2 certificate for its Software-as-a-Service subscription for enterprise imaging, Sectra One Cloud, following an assessment according to the framework of the Cloud Security Alliance (CSA). Thi...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.11.2024
EUZ
LISTED
XETR
Eckert & Ziegler mit starken Neunmonatszahlen 2024 weiter auf Wachstumskurs
News Preview
Berlin, 14. November 2024. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) konnte ihren Umsatz in den ersten neun Monaten 2024 im Vergleich zum Vorjahreszeitraum um 17% auf 215,5 Mio. € steigern. Das EBIT vor Sondereinflüssen aus fortgeführten Geschäftsbereichen (bereinigtes EBIT) stieg um 24% auf 46,7 Mio. €. Der Nettogewinn (aus fortgefüh......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.11.2024
EUZ
LISTED
XETR
Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
News Preview
Berlin, November 14, 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 m......
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
AGFB
LISTED
EURONEXT
The Agfa-Gevaert Group in Q3 2024: stable sales, adjusted EBITDA at 15 million euro - regulated information
News Preview
Regulated information November 14, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2024: stable sales, adjusted EBITDA at 15 million euro...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
AGFB
LISTED
EURONEXT
Agfa announces plan to adjust the cost base of its traditional film activities to the reality in the market - regulated information
News Preview
...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Proposed Public Offering of American Depositary Shares
News Preview
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $200.0 million of American depositary shares (“ADSs”), each representing ten ordinary shares of the Company with a par value of $0.000006 per sh...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
GNFT
LISTED
EURONEXT
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead of The Liver Meeting 2024®2....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
ZEAL
LISTED
CPH
Zealand Pharma to participate in the Jefferies London Healthcare Conference
News Preview
Press Release – No. 11 / 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
SLP
LISTED
NASDAQ
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
RXRX
LISTED
NASDAQ
Recursion and Exscientia Shareholders Approve the Proposed Combination
News Preview
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
ICLR
LISTED
NASDAQ
ICON plc to Present at the Jefferies London Healthcare Conference
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:00am GMT.
Any changes to this event and links to the live...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
HELP
LISTED
NASDAQ
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM, its Phase 3 pivotal program evaluating the efficacy and saf...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
DFTX
LISTED
NASDAQ
MindMed to Participate in Upcoming Investor Conferences
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
Jefferies London Healthcare Conference
F...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
ATAI
LISTED
NASDAQ
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
News Preview
Q3 2024 earnings...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
MURA
LISTED
NASDAQ
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
News Preview
Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
POAI
LISTED
NASDAQ
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
News Preview
Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
KDEV
LISTED
STO
Karolinska Development’s Extraordinary General Meeting 2024
News Preview
STOCKHOLM, SWEDEN – November 13, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held an Extraordinary General Meeting on November 13, 2024, at which the shareholders resolved as follows....
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2024
EUZ
LISTED
XETR
Eckert & Ziegler und Telix Pharmaceuticals schließen Kooperations- und Lizenzvertrag für Actinium-225
News Preview
Berlin, 13. November 2024. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) hat heute mit Telix Pharmaceuticals Limited (Telix) einen Kooperations- und Lizenzvertrag über die von Eckert & Ziegler verwendete Zyklotron-Technologie zur Herstellung von Ac-225 unterzeichnet. Der Vertrag sichert Eckert & Ziegler Meilensteinzahlungen von in......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2024
EUZ
LISTED
XETR
Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
News Preview
Berlin, 13 November 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix total......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2024
CLBX
LISTED
AIMX
ANGLE presents two posters at EACR
News Preview
PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
IMMNOV
LISTED
STO
Invitation to Immunovia's Q3 presentation
News Preview
LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO an...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
IMMNOV
LISTED
STO
Invitation to Immunovia's Q3 presentation
News Preview
LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO an...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
CYRX
LISTED
NASDAQ
Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
News Preview
Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs
NASHVILLE, Tenn., Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
TEM
LISTED
NASDAQ
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates.
“In the third quarter, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines,” said Dr. Sam...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
